RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RxSight (NASDAQ: RXST) reported that on July 24, 2026 it granted inducement equity awards to new President and CEO Aziz Mottiwala in connection with his employment. The awards include stock options for 571,286 shares at an exercise price of $5.19 and RSUs covering 2,312,138 shares.
The options vest 25% on the one-year anniversary of July 24, 2026, with the remainder vesting in equal monthly installments over the following three years. The RSUs vest 20% on each of the first two anniversaries and 60% on the third anniversary. The grants were made under the 2026 Inducement Equity Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Positive
- 571,286 stock options granted at $5.19, equal to grant-date closing price
- Time-based vesting over four years for options supports long-term leadership retention
- RSU grant covering 2,312,138 shares vests over three years, aligning CEO with shareholder value
- Awards made under 2026 Inducement Equity Incentive Plan in compliance with Nasdaq Rule 5635(c)(4)
Negative
- Large equity awards of over 2.8 million shares represent significant share-based compensation over time
News Explained
The grant creates a staged path to additional shares, so existing holders face potential ownership dilution rather than immediate issuance of all covered shares.
RxSight granted the awards on
The 571,286 options require exercise at
The 2,312,138 RSUs vest
Details
Market move: RXST +8.67% in the Jul 27 session. leadership inducement grants
On Jul 27, the first trading day after this news, RXST closed 8.67% above the previous close. Argus tracked a peak move of +3.9% during that session. Our momentum scanner recorded 9 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 27 session.
Key Figures
- Inducement stock options
- 571,286 shares
- Granted July 24, 2026
- Inducement RSUs
- 2,312,138 shares
- Granted to the new CEO
- Exercise price
- $5.19 per share
- Equal to the closing price on the grant date
- Option first vesting tranche
- 25%
- Vests on the one-year anniversary
- Monthly option vesting
- 1/48th
- Vests monthly after the first-year tranche
- RSU first vesting tranche
- 20%
- Vests on the one-year anniversary
- RSU second vesting tranche
- 20%
- Vests on the two-year anniversary
- RSU final vesting tranche
- 60%
- Vests on the three-year anniversary
Historical Context
-
Mottiwala became CEO while Kurtz transitioned to chief medical officer
-
Preliminary Q2 results and revised full-year outlook followed Alcon collaboration
-
Alcon agreement included upfront payment, milestones and royalties for adjustable lenses
-
Management scheduled a fireside chat at the Stifel ophthalmology forum
-
Q1 revenue declined year over year and the company reported a net loss
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
inducement stock options financial
restricted stock units financial
vesting financial
Nasdaq Listing Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight’s common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight’s common stock to Aziz Mottiwala, RxSight’s new President and Chief Executive Officer in connection with his commencement of employment with RxSight.
The inducement stock options have an exercise price of
The inducement RSU award shall vest as follows:
Each inducement award is subject to the terms of the RxSight, Inc. 2026 Inducement Equity Incentive Plan and related forms of agreements, and were granted as inducements material to Mr. Mottiwala to enter into employment with RxSight in accordance with Nasdaq Listing Rule 5635(c)(4).
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL/LAL+, collectively the “LAL”), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.